Clinical Trial Update: Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants [Phase 3]

View source ↗

Summary

Phase 3 study assessing pharmacokinetic effects of QTI571 on sildenafil and bosentan in pulmonary arterial hypertension; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Bosentan (Bosentan)
• QTI571 (QTI571)
• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2021-06-21